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Abstract
Background: The “Age of Blood in Children in Pediatric Intensive Care Unit” (ABC PICU) study is a randomized
controlled trial (RCT) that aims to determine if red blood cell (RBC) unit storage age affects outcomes in critically ill
children. While RBCs can be stored for up to 42 days in additive solutions, their efficacy and safety after long-term
storage have been challenged. Preclinical and clinical observational evidence suggests loss of efficacy and lack of
safety of older RBC units, especially in more vulnerable populations such as critically ill children. Because there is a
belief that shorter storage will improve outcomes, some physicians and institutions systematically transfuse fresh
RBCs to children. Conversely, the standard practice of blood banks is to deliver the oldest available RBC unit (first-in,
first-out policy) in order to decrease wastage.
Methods/design: The ABC PICU study, is a double-blind superiority trial comparing the development of “New or
Progressive Multiple Organ Dysfunction Syndrome” (NPMODS) in 1538 critically ill children randomized to either
transfusion with RBCs stored for ≤ 7 days or to standard-issue RBCs (oldest in inventory). Patients are being
recruited from 52 centers in the US, Canada, France, Italy, and Israel.
Discussion: The ABC PICU study should have significant implications for blood procurement services. A relative risk
reduction of 33% is postulated in the short-storage arm. If a difference is found, this will indicate that fresher RBCs
do improve outcomes in the pediatric intensive care unit population and would justify that use in critically ill children.
If no difference is found, this will reassure clinicians and transfusion medicine specialists regarding the safety of the
current system of allocating the oldest RBC unit in inventory and will discourage clinicians from preferentially requesting
fresher blood for critically ill children.
Trial registration: ClinicalTrials.gov, ID: NCT01977547. Registered on 6 November 2013.
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Background
Red blood cells (RBCs) are transfused in anemic patients
primarily to maintain or to improve oxygen (O2) delivery
and consumption by vital organs and, therefore, prevent
or reverse O2 debt, which may result in shock and/or
multiple organ dysfunction syndrome (MODS). Standard
policy for the majority of children in North American
and European hospitals is to dispense the oldest RBC
unit available in the blood bank [1, 2]. While this approach
limits wastage, the impact upon transfusion efficacy and
safety, specifically in critically ill populations, is a concern
due to immune modulation, decreased RBC deformability,
altered nitric oxide metabolism, and increased coagulation
[3–5]. Regulatory agencies have established the upper
limit of RBC storage based upon mean hemolysis of less
than 1% (0.8% in Europe) and > 75% of transfused circulat-
ing RBCs still viable in healthy volunteers 24 h after trans-
fusion [6, 7]. This has led to a limit of up to 42 days of
storage in additive solutions in the US and Canada as well
as in many European countries. These regulations do not
consider the numerous biochemical, structural, inflamma-
tory, and physiologic changes that occur in RBC units
during storage (the “RBC storage lesion”), which may be
deleterious to vulnerable populations [3, 7–12].
Clinical studies examining RBC storage age and outcomes
Preclinical studies have showed that transfusion with
RBCs stored for > 7 days can have adverse effects on
microcirculatory flow and O2 utilization [5, 13]. Numerous
clinical studies in humans, however, have observed conflict-
ing results when comparing “older, less fresh” RBCs with
“younger, fresh” transfused products including eight ran-
domized controlled trials (RCTs), 32 observational studies,
and several meta-analyses in varied patient populations
[14–20]. Observational studies in critically ill patients have
mostly reported an independent association between in-
creased RBC age and organ failure or increased mortality
[1, 21–25]. However, these studies, due to the nature of
their design are often confounded by indication bias, as well
as other sources of significant bias. Heterogeneous distribu-
tion of relatively old and young RBCs and the correlation of
transfusion volumes and frequency of transfusion, which
may reflect higher severity of illness, with storage age
hinder evaluation of the independent effect of storage
age on outcomes [26, 27].
The impact of transfusing older RBC units on morbid-
ity and mortality, specifically in critically ill populations,
thus remains a concern [22, 27–30].
Several randomized trials have been carried out in critic-
ally ill adults [31–35] and two trials have also been pub-
lished in unique pediatric populations that have addressed
the question [36, 37]; except for the ARIPI trial, all these
were published after starting ABC PICU. While these trials
provide evidence to guide RBC transfusion practices and
blood banking policies in these populations, they did not
find difference by RBC age with respect to the outcomes
they were studying and do not provide the evidence re-
quired to guide practice in critically ill children – one of
the only populations where fresh blood is being routinely
being used [38]. The “Age of Blood in Children in Pediatric
Intensive Care Unit” (ABC PICU) trial is a definitive study
designed to address the question of whether transfusion of
RBC units stored for 7 days or less reduces organ failure or
death in critically ill children.
Methods/design
Study design
The ABC PICU trial is a large multicenter, international,
double-blind, superiority, two-arm RCT. It will compare
the risk of New or Progressive Multiple Organ Dysfunc-
tion Syndrome (NPMODS) between patients transfused
RBCs of decreased storage age (length of storage ≤7 days)
and those transfused standard-issue RBCs (stored for 2–
42 days; expected average length of storage of about 17–
21 days). The sample size of the trial is 1538 children
and we are enrolling from a wide variety of pediatric
hospitals in the US, Canada, France, Italy, and Israel. A
summary of the protocol is provided in Table 1 (World
Health Organization trial registration dataset) and in
Additional file 1 (Standard Protocol Items: Recommen-
dations for Interventional Trials (SPIRIT) Checklist).
Trial hypothesis
The hypothesis is that transfusion of RBC units stored
for ≤ 7 days (definition of short storage) in critically ill
children will reduce the proportion of patients who de-
velop NPMODS, which includes death, within 24 days of
randomization. We expect a reduction of at least 6%
(33% relative risk reduction), from 18% in children
receiving standard-issue RBCs to 12% in the “short-sto-
rage” group.
Study population
Site eligibility requires validation that the site has the
ability to perform the trial, confirmation by site survey
that its blood bank(s) can provide short-storage RBC
units as required as well as that the standard-issue RBCs
will have a median storage age of at least 15 days. The
ABC PICU study imposes minimal restrictions on patient
eligibility, no controls on clinical practice and has opted to
assess clinically important outcomes for pediatric critical
illness.
Screening
Patients from 52 centers are screened and consented for
randomization via three primary means (Fig. 1):
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Table 1 World Health Organization trial registration dataset
Primary registry and trial identifying
number
ClinicalTrials.gov, ID: NCT01977547
Date of registration in primary registry 5 November 2013
Secondary identifying numbers None
Source(s) of monetary or material support 1. National Heart, Lung and Blood Institute (Grant #1U01HL116383–01);2. Canadian Institutes of
Health Research (Grant #126113), Ottawa, ON, Canada; 3. Comité National de la Recherche Clinique,
Département de la Recherche Clinique et du Développement (DRCD), Assistance Publique – Hôpitaux
de Paris, Ministère des Solidarités, de la Santé et de la Famille, France; 4. Ministère des Affaires
Sociales et de la Santé, Paris, France (PHRC 14–0390);
5. The Ministère de la Santé et des Services Sociaux de la Province de Québec; and
6. Department of Pediatrics, Washington University in St. Louis, St. Louis, MO, USA
Primary sponsor Investigator-initiated study
Philip C. Spinella MD, FCCM
Associate Professor of Pediatrics
Division of Pediatric Critical Care
Washington University in St. Louis
St. Louis Children’s Hospital
Campus Box 8116
One Children’s Place/NWT 10th fl.
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Phone: (514) 345–4931 × 3261
Email: marisa.tucci@recherche-ste-justine.qc.ca
Secondary sponsor(s) Washington University in St. Louis
St. Louis Children’s Hospital
CHU Sainte-Justine
Université de Montréal
Contact for public queries Philip C. Spinella MD, FCCM, Washington University in St. Louis, St. Louis Children’s Hospital, Campus
Box 8116, One Children’s Place/NWT 10th fl., St. Louis, MO 63110, USA
Phone: (314) 286–0858
Email: spinella_p@kids.wustl.edu
Marisa Tucci, MD, Sainte-Justine Hospital, 3175 Côte Sainte-Catherine, Montreal, QC, Canada H3T 1C5
Phone: (514) 345–4931 × 3261
Email: marisa.tucci@recherche-ste-justine.qc.ca
Contact for scientific queries Philip C. Spinella MD, FCCM, Washington University in St. Louis, St. Louis Children’s Hospital, Campus
Box 8116, One Children’s Place/NWT 10th fl., St. Louis, MO 63110, USA
Phone: (314) 286–0858
Email: spinella_p@kids.wustl.edu
Marisa Tucci, MD, Sainte-Justine Hospital, 3175 Côte Sainte-Catherine, Montreal, QC, Canada H3T 1C5
Phone: (514) 345–4931 × 3261
Email: marisa.tucci@recherche-ste-justine.qc.ca
Public title Age of Blood in Children in Pediatric Intensive Care Units
Scientific title The Age of Blood in Pediatric Intensive Care Units (ABC PICU) Randomized Clinical Trial
Countries of recruitment Canada, US, France, Italy, Israel
Health condition(s) or problem(s) studied Impact of red blood cell storage time on multiple organ dysfunction syndrome in critically ill children
Intervention(s) Transfusion with either RBCs stored for ≤ 7 days or standard-issue red blood cells (oldest in inventory)
Key inclusion and exclusion criteria Eligible for study: 1. a first RBC transfusion is requested within the first 7 days (168 h) of PICU admission;
or 2. patient assessed pre-operatively and for whom PICU admission is planned post-operatively, and
who is determined to definitively require a first RBC transfusion during surgery
Inclusion criteria: critically ill pediatric patients who have an expected length of stay after transfusion
in the ICU > 24 h based on the best judgment of the attending ICU staff
Exclusion criteria: age at ICU entry < 3 days from birth or > 16 years of age;
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1. The clinical status and laboratory hemoglobin levels
of PICU patients in ICU at high risk for RBC
transfusion are monitored by research staff who
verify eligibility, inclusion and exclusion criteria. If
the patient meets all criteria, consent is obtained.
Then, if RBC transfusion is ordered in the PICU
(independent of the trial) within the first 7 days
after admission, the patient is randomized. This
period of eligibility is justified because the rate of
NPMODS is low after 7 days in PICU (< 2%) [39]
2. A RBC transfusion is ordered in the PICU in a
patient not identified via 1. Research staff verify
inclusion and exclusion criteria. If the patient meets
all criteria, consent is obtained and the patient is
randomized
3. A patient who will require PICU admission post-
operatively and for whom the surgeon deems a
RBC transfusion will definitively be required intra-
operatively. Research staff verify eligibility, inclusion
and exclusion criteria. If the patient meets all criteria,
consent is obtained pre-operatively. The patient is
randomized when RBCs are requested for the
operating room in preparation for surgery
Written informed consent from the patient or their
legal guardian is required prior to randomizing a patient.
Assent is obtained from the child whenever possible ac-
cording to Institutional Review Board (IRB) requirements
at each site.
Patient eligibility
A patient is considered eligible to participate in the trial
if one of the following occurs: (1) a first RBC transfusion
is requested within the first 7 days (168 h) of PICU ad-
mission; (2) a patient is assessed pre-operatively and, if
PICU admission is planned, post-operatively, and deter-
mined to definitively require a first RBC transfusion dur-
ing surgery. In either case, the patient must have an
expected length of stay after transfusion in the PICU >
24 h based on the best judgment of the attending staff.
Patients who meet any of the criteria listed in Table 2
are excluded.
Clinical and outcome information
A schedule of enrollment, interventions and assessments
is reported in Fig. 2. ICU data collected is listed in Table 3.
Baseline data at admission includes co-morbidities, type of
ICU admission, blood type, and hemoglobin prior to first
RBC transfusion. Clinical and outcome data, as well as the
Pediatric Logistic Organ Dysfunction version 2 (PELOD-2)
score and specific MODS information, are collected daily
through day 7 after randomization, then on days 14, 21,
Table 1 World Health Organization trial registration dataset (Continued)
post-conception age < 36 weeks on admission to ICU; documented RBC transfusion within the 28 days
prior to fulfilling the eligibility criteria; previously randomized in this study; weight < 3.0 kg on ICU
admission; pregnant; conscious objection or unwillingness to receive blood products; not expected to
survive beyond 24 h, brain death or suspected brain death; limitation or withdrawal of care decisions
have been made; enrollment in another randomized clinical trial which has not been approved for
co-enrollment; patients for whom autologous and/or directed donation RBCs will be provided; patients
for whom the treating physician routinely and systematically requests RBC≤ 14 days of storage; patients
for whom there systematically exist RBC aliquoting policies that mandate the initial use of units stored
for ≤ 14 days; on ECMO or plan to be immediately placed on ECMO at time of enrollment; patient
predicted or presumed to require a massive transfusion (> 40 ml/kg of all blood components in a 24-h
period) according to treating physician judgment; refusal by physician; inability to obtain consent; blood
bank personnel experiences difficulties in securing blood products (difficult cross matches, rare blood
groups, and diseases like IgA deficiency); insufficient number of ABO type compatible RBC units available
in the blood bank at randomization with a storage time≤ 7 days (minimum 1 unit regardless of patient
age); all RBC units available for the patient are not leukocyte-reduced prior to storage
Study type Multicenter, double blind, randomized controlled trial
Date of first enrollment 1 February 2013
Target sample size 1538
Recruitment status Recruiting
Primary outcome New or progressive multiple organ dysfunction syndrome
Key secondary outcomes PICU and hospital mortality, 28-day, and 90-day all-cause mortality, nosocomial infections, PELOD-2
score, severe sepsis, septic shock, acute respiratory distress syndrome (ARDS), mechanical ventilation
and PICU-free days
Ethics review Approval obtained from the Institutional Review Board / Research Ethics Board of all participating sites
and were in accordance with the institutional policies of the US Department of Health and Human
Services in the US, provincial legislation in Canada, and appropriate entities in France, Italy, and Israel
Estimated completion date June 2018
ECMO extracorporeal membrane oxygenation, ICU intensive care unit, PELOD-2 pediatric logistic organ dysfunction version 2, PICU pediatric intensive care unit,
RBC red blood cell
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Fig. 1 Screening, eligibility, consent, and randomization scenarios
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and 28. This data elements are also collected at ICU
discharge if the patient is discharged prior to day 28.
Proposed duration of monitoring of RBC transfusion
(study intervention), co-interventions, and follow-up
for the primary outcome NPMODS is 28 days follow-
ing randomization or until PICU discharge or death,
whichever happens first.
Interventions
The trial interventions are either short-storage RBCs
(stored for ≤ 7 days) or standard-issue RBCs. All RBC
units are prepared in accordance with international stan-
dards. All blood products including the RBCs studied in this
trial are supplied by the hospital blood bank according to
applicable local regulations. Only pre-storage leukoreduced
Table 2 Exclusion criteria
1 Age at ICU entry < 3 days from birth or > 16 years of age
2 Post-conception age < 36 weeks on admission to ICU
3 Documented RBC transfusion within the 28 days prior to fulfilling the eligibility criteria
4 Previously randomized in this study
5 Weight < 3.0 kg on ICU admission
6 Pregnant
7 Conscious objection or unwillingness to receive blood products
8 Not expected to survive beyond 24 h, brain death or suspected brain death
9 Limitation or withdrawal of care decisions have been made
10 Enrollment in another randomized clinical trial which has not been approved for co-enrollment
11 Patients for whom autologous and/or directed donation RBCs will be provided
12 Patients for whom the treating physician routinely and systematically requests RBC≤ 14 days of storage
13 Patients for whom there systematically exist RBC aliquoting policies that mandate the initial use of units stored for ≤14 days (ex: Pedi-Pack)
14 On ECMO or plan to be immediately placed on ECMO at time of enrollment
15 Patient predicted or presumed to require a massive transfusion (> 40 ml/kg of all blood components in a 24-h period) according to treating
physician judgment
16 Refusal by physician
17 Inability to obtain consent
18 Blood bank personnel experiences difficulties in securing blood products (difficult cross matches, rare blood groups, and diseases like IgA
deficiency)
19 Insufficient number of ABO type compatible RBC units available in the blood bank at randomization with a storage time≤ 7 days
(minimum 1 unit regardless of patient age)
20 All RBC units available for the patient are not leukocyte-reduced prior to storage
Exclusion criteria # 1 to 17 are ascertained by the research staff with the assistance of the attending ICU team
Exclusion criteria # 18 to 20 are ascertained by blood bank personnel
ECMO extracorporeal membrane oxygenation, ICU intensive care unit, RBC red blood cell
Fig. 2 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) Figure: schedule of enrollment, interventions, and assessments
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RBC units are used in this trial as per local standards
of care.
Randomization and treatment allocation
Patients are randomized to receive either (1) short-storage
RBCs (stored for ≤ 7 days) or (2) standard-issue RBCs
(stored for 2 to 42 days). Inventory management requires
that randomization can occur only when there are RBCs
≤ 7 days and RBCs ≥ 5 days available to meet the cross-
match request.
The randomization process is being done using an
Internet-based system and consists of an Internet-based,
computer-generated random listing of treatment alloca-
tion using a pre-established algorithm. Allocation is in a
1:1 ratio. Patients are stratified at randomization accord-
ing to center and age (≤ 28 days after the day of birth,
29 to 365 days, and > 1 year). Stratification by site and
age is employed as unbalanced treatment allocation is
possible given the diversity in case mix within each of
the participating PICUs. In order to conceal future allo-
cation, three sizes of block permutation (2, 4, and 6 pa-
tients per block) are randomly used in each stratification
tree via a computer-generated randomization scheme.
Blinding
Blinding is used not only in the allocation process (con-
cealment of randomization), but also in the intervention
allocation (fresh versus standard delivery). The blood
bank technologist verifies the expiry date of the RBC
unit prior to its release, registers the date of collection of
the RBC unit delivered and refrains from releasing infor-
mation on the storage times of RBC units to clinical
personnel. Thus, physicians, nurses, other caregivers and
research staff are not given any information regarding in-
dividual entries from the computer-generated random list.
To blind clinicians and research personnel, opaque
stickers are placed on expiration dates on the labels affixed
to bags of RBC units in the blood bank before any RBC
unit is delivered to a patient participating in ABC PICU.
In France, blinding occurs by re-printing a blood-bag label
on which the expiry/collection date was no longer show-
ing. Accidental un-blinding of the RBC unit expiration
date is documented and reported via the protocol devi-
ation process. The data of study patients with accidental
un-blinding will be included in the intent-to-treat (ITT)
analysis.
Outcome evaluation, diagnosis of NPMODS and the
determination of all scores are done by research assis-
tants who are unaware of treatment allocation.
Compliance
Measures to ensure adherence
Measures instituted to highlight trial participation and
to maximize protocol adherence include: (1) provision of
institute-specific protocols for inventory management of
RBC units for the trial and tracking of patients enrolled
in the trial, (2) monitoring of RBC supply in some sites to
ensure adequate supplies are available for randomization,
(3) audits on the age of RBCs entered in the system to
identify sites that may have issues to address, and (4)
mechanisms to allow for appropriate RBCs (short storage
Table 3 ICU data collected
• Demographic data
• Baseline data
• PRISM III score
• PELOD-2 score
• Clinical data for organ dysfunctions
• Red blood cell transfusion information
• Mechanical ventilation
• Evidence of infection
◦ nosocomial pneumonia




• Acute respiratory distress syndrome
• Deep venous thrombosis
• Any transfusion reaction
• Critical care interventions
◦ length of mechanical ventilation
◦ hemodynamic support
◦ renal replacement therapy
◦ fluid balance per day
◦ proportion of patients receiving erythropoietin
◦ vasoactive drugs
◦ mild to moderate hypothermia treatment
◦ systemic corticosteroids
◦ insulin administration
◦ starch colloids and/or gelatins
◦ plasmapheresis
◦ Molecular Adsorbent Re-Circulating System (MARS)
• Tranfusion interventions other than RBC administration







ICU intensive care unit, PELOD-2 Pediatric Logistic Organ Dysfunction version
2, PRISM III Pediatric risk of mortality
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versus standard issue) to be transferred from other local
sites or from blood providers. Patients who receive no
transfusion in the 28 days after randomization will be ex-
cluded from the per-protocol analysis. It might occur very
rarely that a patient in the standard-issue arm is moved to
the short-storage arm. If this was to occur, these patients
will also be considered as non-compliant and will be re-
moved from the per-protocol primary analysis but will be
kept in the ITT analysis.
Compliance with the intervention
Patients in the short-storage arm of the study are consid-
ered adherent to protocol if 80% or more of transfused
RBCs are stored for ≤ 7 days and if they receive no RBC
unit stored for > 14 days during the 28-day follow-up
period. If not, data for that subject will be removed from
the per-protocol analysis.
The clinical team can administer any available RBCs
regardless of storage time to patients who become un-
stable and have transfusion requirements that do not
allow for adherence to the protocol.
The decision to withhold or to withdraw critical care
will not be considered an exclusion criterion if it occurs
after a patient enters the trial. These cases will be kept
in the ITT analysis.
Outcomes
Primary outcome measure
The primary outcome measure is rate of 28-day
NPMODS, defined as the proportion of patients who die
during the 28 days after randomization or who develop
NPMODS including mortality. For patients with no organ
dysfunction at randomization, “New MODS” is the devel-
opment of two or more concurrent organ dysfunctions;
for patients with one organ dysfunction at randomization;
New MODS is the development of at least one other con-
current organ dysfunction; patients with MODS (i.e., con-
current dysfunction of two or more organ systems) at
randomization can develop “Progressive MODS” defined
as the development of at least one additional concurrent
organ dysfunction. All deaths are considered Progressive
MODS. NPMODS is monitored daily for the first 7 days
following randomization and then weekly up to 28 days or
PICU discharge because it is almost never observed be-
yond this time in children [39].
Secondary outcome measures
Secondary outcomes include PICU and hospital mortal-
ity, 28-day, and 90-day all-cause mortality. Nosocomial
infections will be recorded, including nosocomial pneu-
monia and bloodstream infection. Other secondary out-
comes include PELOD-2 score, which measures the
severity of MODS [40, 41], severe sepsis, septic shock,
acute respiratory distress syndrome, mechanical venti-
lation and PICU-free days.
Adverse events and serious adverse events
The list and definitions of adverse events and transfusion
reactions as well as reporting timelines are described in
Additional file 2.
Sample size
Patient eligibility criteria and short-storage definition
(7-day cutoff ) in ABC PICU will be similar to those used
in preliminary studies (Table 4) [1, 23]. Based on this
prior work and on a large survey of North American
intensivists [38], the incidence of NPMODS is expected
to be 18% in the control group and 12% in the
short-storage group and the relative risk is expected to
be 33%. Sample size calculations based on these esti-
mates for two independent proportions (chi-square)
using a two-tailed α of 0.05 and a (1 − β) of 0.90 yield an
estimate of 769 patients per arm (total: 1538) [42]. The
ABC PICU Trial Steering Committee, the CCCTG
(www.ccctg.ca), and the PALISI Network (www.palisi.org)
support these estimates and the choice of a 33% relative
risk difference because it is considered clinically important
and sufficiently significant to change practice. The propor-
tion of patients lost to follow-up is expected at 1.7% based
on results of the TRIPICU study. The sample size for the




Baseline characteristics of patients, intervention, and
co-interventions in both study arms will be assessed
using frequency distributions and univariate descriptive
Table 4 Estimates for the absolute risk reduction expected in
the ABC PICU trial
Analytic cohort study:
Gauvin et al. [1]
Descriptive
cohort study:
Karam et al. [2]
Storage time cutoff for “fresh”
RBC unit
7 days 7 days




NPMODS in transfused patients 15% 39.2%
Odds ratio for development
of NPMODS in older versus
fresher (confidence interval)
1.39 (0.42–4.61) 1.54 (0.80–2.96)
Estimated risk in experimental
group 1/OR = (p1/(1 − p1))/
(p0/(1 − p0))
11% 22%
MODS multiple organ dysfunction syndrome, NPMODS new or progressive
multiple organ dysfunction syndrome, OR odds ratio, PICU pediatric intensive
care unit, RBC red blood cell, RCT randomized controlled trial
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statistics including measures of central tendency and
dispersion. Mean (± standard deviation) and median
(interquartile range) will be used to report data as appro-
priate. Percentages will be reported for categorical data.
Any known clinical risk factor, whether or not there is a
statistically significant imbalance, will be considered for
adjusted analyses of primary and secondary outcomes.
Intervention and co-interventions
Post-randomization characteristics of the intervention
(short storage versus standard issue RBC units) and major
co-interventions (platelets, plasma, fluid balance, etc.) will
be presented using frequency distributions with measures
of central tendency and dispersion, and analyzed using
relative risks and 95% confidence interval (CI) for dichot-
omous data (e.g., proportion transfused with platelets) and
Wilcoxon Rank Sum tests for difference in continuous
data (e.g., difference in median platelet use).
Analysis of the primary outcome measure
As this is an effectiveness trial, the analysis of the primary
outcome measure will be conducted on an ITT approach.
Data from all participants enrolled will be analyzed ac-
cording to the intervention to which they were allocated,
regardless of whether it was received or not (Fig. 3). The
primary outcome (i.e., the effect of treatment, short stor-
age versus standard issue, on development of NPMODS),
will be analyzed using an unadjusted chi-square. The prin-
cipal effect measure will be an unadjusted relative risk re-
duction with a 95% CI. A per-protocol analysis of the
primary outcome measure will also be done. Sensitivity
analysis will be performed that excludes patients in the
short-storage group who receive RBCs stored for > 7 days
and patients in the standard-issue arm who receive RBCs
stored for ≤ 7 days. Hypothesis testing for the primary
analysis will be carried out with an overall level of signifi-
cance set using a p value < 0.05, taking into account one
interim analysis with the p value being determined by the
O’Brien-Fleming stopping rule [43]. All p values will be re-
ported as two-sided.
Secondary analyses of the primary outcome (NPMODS)
include a logistic regression model to further elucidate the
measure of effect while adjusting for known prognostic fac-
tors or those thought to be associated with multiple organ
failure. For associated prognostic risk factors, independent
covariates, such as center, age, gender, and co-morbid ill-
nesses, and severity of illness scores, will be added to all
logistic models. Potential confounding factors, if clinically
relevant, will be considered for inclusion into logistic
models. Continuous risk factors (e.g., pediatric risk of mor-
tality (PRISM) III, number of transfusions per patient) will
be entered into the models as a continuous measure rather
than categorical to improve statistical efficiency. Regression
diagnostics will be performed on all models. We will plot
Fig. 3 Intent-to-treat (ITT) analysis
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continuous variables and check for linearity before in-
cluding in regression models. Variables not meeting a
reasonable linearity assumption will be transformed.
Odds ratios will be estimated from coefficients and CIs
will be constructed using Robins-Greenland procedures
[44]. Kaplan-Meier curves will be compared using a
log-rank test followed by proportional hazards model-
ing for NPMODS rates: this analysis will compare the
length of time between randomization and onset of
NPMODS.
Analyses of secondary outcome measures
As with the primary outcome, secondary outcome mea-
sures will be analyzed by an ITT approach. The effect of
treatment on dichotomous secondary outcomes will be
determined by calculating relative risk reduction and
relative risks followed by logistic regression procedures.
Continuous outcome measures, such as the PELOD-2
score, mechanical ventilation days, ventilator-free days,
PICU length of stay, and PICU-free days, will be ana-
lyzed using either parametric procedures (independent t
test) or non-parametric procedures (Wilcoxon Rank
Sum). The influence of treatment groups (short storage
versus standard issue) on categorical variables, including
mortality and infectious complications, will be analyzed
using either parametric or non-parametric procedures
followed by multiple comparison procedures (e.g., sequen-
tially rejective Bonferroni procedure), as deemed appropri-
ate. Interactions will be sought between RBC storage time
and other parameters with respect to the primary outcome
such as the severity of organ dysfunction, the highest num-
ber of organ dysfunctions, and the PELOD-2 score (patients
who die will be assigned the worst possible NPMODS score
at the time of death). This includes an analysis based on the
number of units transfused. Per-protocol analyses under-
taken for secondary outcomes will be only exploratory.
Subgroup analyses
Subgroup analyses are planned for: (1) illness category
(cardiac surgery, general surgery, trauma, medical), (2)
volume/kg of RBCs transfused (analyzed by quartiles
and other methods), (3) severity of illness at baseline, as
evaluated by the PRISM III score [45], (4) stable versus
unstable patients at the time of first transfusion (as de-
fined in the TRIPICU study) [46], and (5) ABO type.
The analytic approach used for all subgroup analyses will
be ITT. Interactions between treatment group in subgroup
categories specified above will be calculated. Interactions
will be assessed by adding the treatment, subgroup of
interest (categorized), and its interaction term (treat-
ment × subgroup) in a multivariate logistic regression
model. We recognize the limitations of subgroup analyses
(low power, type I error, difficulties in interpretation)
[47]. These analyses will be hypothesis-generating and
hypothesis-supporting in nature.
Excluded patients
A limited analysis will be conducted on all patients meet-
ing the inclusion and exclusion criteria but who were not
randomized, using data in the screening log, to ascertain if




Data management is performed at the Ottawa Health
Research Institute under the supervision of the study
statistician (DF) at this site. Data is entered on site in
the web-based electronic case report form (eCRF). During
the validation phase, the case report form (CRF) and entries
were considered adequate if the frequency of discordance
was lower than 2% in the CRF. The Data Management
Center (DMC) and the Coordinating Centers (Sainte-
Justine Hospital, University of Montreal, and St. Louis
Children’s Hospital, Washington University School of
Medicine) are responsible for data quality assurance done
through eCRF (via regular data extraction) and queries. A
second satellite Data Management Center (DMC) was
created in St. Louis that involved a study statistician (KS).
The St. Louis DMC has three overarching responsibilities:
(1) development and implementation of an automated
query generation system, (2) Data and Safety Monitoring
Board (DSMB) report completion, and (3) adverse event
monitoring and reporting. Data is uploaded every other
week for the duration of the study at this site; all data is
automatically encrypted when the transfer takes place.
Interim analysis
The DSMB of the ABC PICU trial requested that an in-
terim analysis be done when enrollment and completed
data collection reached 50% of recruitment targeted.
The interim statistical analysis will compare NPMODS
rates in the short-storage and standard-issue groups, using
O’Brien-Fleming stopping rules [43], with a two-tailed p
value. Stopping rules are based upon safety concerns as
assessed by the DSMB. The DSMB of the ABC PICU trial
could consider terminating enrollment if the statistical
analysis showed a statistically significant difference. Both
positive and negative findings from the ABC PICU trial
are considered of clinical interest.
Study monitoring
The DSMB for ABC PICU was established by the National
Heart Lung and Blood Institute (NHLBI) to monitor data
and oversee patient safety in this study and convenes twice
a year. The principal investigators, staff from the DMC
and NHLBI participate in the meetings as non-voting
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members. Study monitoring methods vary according to
country. For all participating centers throughout the US,
Canada, and Europe, 100% of eCRFs are audited through
automated query process using pre-determined ranges
flagging suspicious or out-of-range values.
For US participating centers, as well as for Italy and
Israel, there are a total of three scheduled site visits
(with the exception for those sites that on-boarded in
2017 where there may only be one or two visits due to
time restraints). These visits are undertaken following
the enrollment of, and completion of, 28-day data of the
first two randomizations at the study interim, and a visit
is planned at study close-out. Additional site visits are
carried out at any time as deemed necessary. For inter-
national sites, a site initiation visit occurred prior to
on-boarding to review the US regulations, study design
and eCRF for clarity. During monitoring visits, a review
of 100% of regulatory documents, IRB/REB paperwork,
consent, and eligibility for compliance are done. A re-
view of all data queries and corrections received to date
is completed to ensure resolution to the extent possible.
At each visit 20–30% of charts are reviewed for primary
and secondary outcomes. In Canada, site initiation was
conducted by teleconference prior to screening start and
included members of the ICU research team, as well as
blood bank personnel. The Canadian Coordinating Center
audited data electronically by extracting and questioning
sites on out-of-range values, as well free-text answers The
Coordinating Center also verified coherence and logic be-
tween variables. The Coordinating Center did not exclude
the option of conducting for-cause monitoring visits; how-
ever, none have been required so far. In France, the CHU
de Lille conducted on-site initiation visits prior to start of
screening.
Close-out and access to data
All data and source documentation will be stored in a
secure storage facility for 7 years from the time of study
close-out. Datasets must be submitted to the study
NHLBI study program official no later than 3 years after
the end of the clinical activity (final patient follow-up,
etc.) or 2 years after the main paper of the trial has been
published, whichever comes first. Data is prepared by
the study coordinating center and sent for review prior
to release. The NIH and NHLBI expect the timely re-
lease and sharing of data to be no later than the accept-
ance for publication of the main findings from the final
dataset.
Discussion
RBCs are the most frequently transfused blood product
with approximately 85 million RBC units transfused
worldwide per year, of which 12–16 million units were
transfused in the US [48]. The blood banking system is
organized to issue the oldest RBC units first to minimize
wastage of this valuable and limited resource. Thus,
RBCs are transfused in critically ill children even if they
have been stored for up to 42 days, despite laboratory
evidence suggesting significant changes to cell structure
and no strong evidence that they remain effective and
safe. There is a widely held belief that the freshest RBCs
possible could benefit critically ill children. Indeed, for
certain patients, such as children undergoing cardiac
surgery, there are already agreements with blood banks
to use only fresh RBCs even though there is no evidence
to support such practice [38]. Further, this practice raises
ethical concerns regarding inequitable use of available
RBC units.
Several recent RCTs in adults, including the Red Cell
Storage Duration Study (RECESS) trial, the Age of Blood
Evaluation (ABLE) randomized controlled trial, the Inform-
ing Fresh versus Old Red Cell Management (INFORM)
trial, and the Standard Issue Transfusion versus Fresher
Red-Cell Use in Intensive Care (TRANSFUSE) trial, have
compared RBC units aged less than 10 days with transfu-
sion of 14- to 42-day-old RBC units in various critically ill
populations [31–34]. In these studies, as well as in a recent
systematic review [35], there was no survival advantage in
transfusing “fresher” blood. However, findings from adult
studies may not be applicable to children because host
characteristics and developmental differences may have a
significant impact on the risks and benefits of anemia and
transfusion in this population [49].
Two RCTs have been published in pediatric populations.
The Tissue Oxygenation by Transfusion in Severe Anemia
With Lactic Acidosis (TOTAL) trial failed to show a differ-
ence in elevated blood lactate levels among children with
severe anemia who received RBCs with a more prolonged
storage time [50]. Most of the children in this trial had mal-
aria or sickle cell disease. Generalizability of the results of
this trial is questionable because RBC transfusion practices,
case mix, and the etiology of shock are different in
more developed countries. The Age of Red Blood Cells
in Premature Infants (ARIPI) trial investigated the effects
of RBC storage in premature neonates and demonstrated
that fresher RBCs did not improve a composite outcome
measure that included major neonatal morbidities, in-
cluding necrotizing enterocolitis, retinopathy of prema-
turity, bronchopulmonary dysplasia, and intraventricular
hemorrhage, as well as death [37]. Except for death, these
outcomes are never seen in non-premature PICU patients.
The ABC PICU trial is designed to definitively address
this question in a large general PICU population repre-
sentative of critically ill children. It will either support
the wide adoption of optimal RBC transfusion practices
in critically ill children. The primary outcome is clinic-
ally relevant and widely accepted. There is consensus
among members of the Pediatric Acute Lung Injury
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(PALISI) and the Canadian Critical Care Trials Group
Networks that results would be clinically meaningful and
practice change would be justified if ABC PICU shows su-
periority for fresher RBC units. Clinically, important sec-
ondary outcomes will be evaluated and pertinent subgroup
analyses are planned. In addition, some exploratory analyses
are being considered that will involve examining the main
effect (storage duration) as a function of RBC dose. Given
that multiple transfusions with RBCs of different ages will
occur in both treatment arms and because 7 days is an arbi-
trary cutoff point, analyses are planned that will assess
whether cut-points other than 7 days are preferable.
Trial status
The ABC PICU trial is evaluating whether fresher RBCs
can reduce NPMODS in a large international cohort
of critically ill children. Patient recruitment began in
February 2013 and is currently ongoing (protocol version:
5 May 2016). Recruitment started at the two coordinating
centers in Canada and the US as well as in four vanguard
sites in the US. There are 30 sites in the US, 10 sites in
Canada, eight sites in France, three sites in Italy and one
site in Israel. Recruitment is expected to continue until
June 2018. Results from this trial should influence transfu-
sion practice regardless of the outcomes. If no difference
is found, this will reassure clinicians and transfusion medi-
cine specialists regarding the safety of the current system
of issuing the oldest RBCs in the inventory and will dis-
courage clinicians from preferentially requesting RBCs of
decreased storage age in critically ill children. If a differ-
ence is found, this will indicate that fresher RBCs improve
outcomes in the PICU population and would justify the
use of fresher RBC use in critically ill children.
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